AnaptysBio, Inc. (ANAB) Hits New 12-Month High at $31.44
AnaptysBio, Inc. (NASDAQ:ANAB) shares reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $31.44 and last traded at $31.44, with a volume of 531,672 shares changing hands. The stock had previously closed at $30.56.
ANAB has been the subject of a number of research analyst reports. Zacks Investment Research raised AnaptysBio from a “sell” rating to a “hold” rating in a report on Monday, May 29th. Robert W. Baird initiated coverage on AnaptysBio in a report on Monday, July 10th. They issued an “outperform” rating and a $36.00 price target for the company. Finally, Credit Suisse Group lifted their price target on AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, August 25th. Six investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $36.00.
The stock’s 50-day moving average price is $24.56 and its 200-day moving average price is $25.08. The firm’s market capitalization is $647.69 million.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7 million for the quarter, compared to the consensus estimate of $3.45 million. Equities analysts predict that AnaptysBio, Inc. will post ($1.96) EPS for the current fiscal year.
In related news, major shareholder Holdings A/S Novo sold 70,706 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the completion of the transaction, the insider now owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,133,940 shares of company stock valued at $24,223,316.
A number of hedge funds have recently bought and sold shares of the stock. DAFNA Capital Management LLC increased its position in AnaptysBio by 22.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 1,000 shares in the last quarter. Teachers Advisors LLC increased its position in AnaptysBio by 23.4% during the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 1,807 shares in the last quarter. Bank of America Corp DE bought a new position in AnaptysBio during the 1st quarter valued at approximately $123,000. TIAA CREF Investment Management LLC increased its position in AnaptysBio by 69.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 13,844 shares of the biotechnology company’s stock valued at $331,000 after buying an additional 5,663 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in AnaptysBio by 46.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,744 shares of the biotechnology company’s stock valued at $473,000 after buying an additional 6,297 shares in the last quarter. 71.35% of the stock is owned by institutional investors.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.